2009 Late-Breaking Science at the Annual Meeting

The Late-Breaking Science program highlights the most current research by neurologists, neuroscientists, and other applicable researchers whose work is of major scientific importance or interest and warrants expedited presentation and publication.

2009 Late-Breaking Science Schedule

LBS: Late-Breaking Science
Wednesday, April 29
WSCC 6B
5:15 p.m.–6:45 p.m.

• LBS.001 "Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)," Gavin Giovannoni, MBBCH, PhD,London, United Kingdom
• LBS.002 "Diffusion Tensor Imaging and mTBI–A Case-Control Study of Blast (+) in Returning Service Members Following OIF and OEF," David F. Moore, MD, PhD, Washington, DC
• LBS.004 "Mutations in the THAP1 gene are responsible for early onset primary torsion dystonia," Susan Bressman, MD, New York, NY
• LBS.005 "Genome-wide Association Studies of Incident Total Stroke and Ischemic Stroke: Meta-analysis and Replication from the CHARGE Consortium," Mohammad Ikram, Rotterdam, Netherlands
• LBS.006 "Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial," Pierre Amarenco, MD, FAAN, Paris, France

LB1: Late-Breaking Science
Wednesday, April 29
WSCC 6E, Poster Session V
11:30 a.m.–2:30 p.m.
(Senior Authors stand-by time 12:00 p.m.–1:30 p.m.)

• LB1.001 "Novel THAP1 Mutations in Primary Dystonia," Mark Ledoux, MD, PhD, Memphis, TN
• LB1.002 "Pregabalin in Restless Legs Syndrome: A double-blind, placebo-controlled study with clinical and polysomnographic assessment," Diego Garcia-Borreguero, MD, Madrid, Spain
• LB1.003 "Allogeneic hematopoietic stem cell transplantation (HSCT) for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)," Michael Schupbach, MD, Bern, Switzerland

LB2: Late Breaking Science
Wednesday, April 29, 2009
WSCC 6E, Poster Session VI
4:00 p.m.–7:00 p.m.
(Senior Author stand-by time 5:30 p.m.–7:00 p.m.)

• LB2.001 "A multicentre, double blind, randomised, placebo-controlled, cross over study of levetiracetam in the prophylaxis of 'Chronic Daily Headache,'" Roy Beran, MD, FAAN, Chatswood, Australia
• LB2.002 "Effect of the BDNF val⁶⁶met Genotype on the Modulation of the Hippocampus by the Mesolimbic Dopaminergic System," Joseph Masdeu, MD, PhD, FAAN, Bethesda, MD
• LB2.003 "Prospective Evaluation of the Effect of Weight Loss on Intracranial Pressure in Idiopathic Intracranial Hypertension," Alexandra Sinclair, MD, Birmingham, United Kingdom

LB3: Late Breaking Science
Thursday, April 30
WSCC 6E, Poster Session VII
7:00 a.m.–10:00 a.m.
(Senior Author stand-by time 7:00 a.m.–8:30 a.m.)

• LB3.001 "Incidence of Acute Leukaemia in Multiple Sclerosis Patients Treated with Mitoxandrone: A Multicentre Retrospective Italian Study," Vittoro Martinelli, Milano, Italy
• LB3.002 "A multi-centre, double blind, randomized, placebo controlled, parallel group trial investigating methylprednisolone (MP) in combination with Interferon-b-1a for the treatment of relapsing-remitting multiple sclerosis (RRMS)," Madx Ravnborg, MD, DMSc, Odense, Denmark

View 2008 Late-Breaking Science Abstracts.

For More Information

For more information about the Late-Breaking Science Program, please contact Kyle Krause at kkrause@aan.com or (651) 695-2733